Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
Status:
Recruiting
Trial end date:
2023-11-15
Target enrollment:
Participant gender:
Summary
This phase I trial studies the best dose and side effects of flotetuzumab for the treatment
of patients with blood cancers (hematological malignancies) that have spread to other places
in the body (advanced) and have come back after a period of improvement (relapsed) or does
not respond to treatment (refractory). Flotetuzumab is a monoclonal antibody that may
interfere with the ability of cancer cells to grow and spread.